×
About 4,193 results

ALLMedicine™ Acne Vulgaris Center

Research & Reviews  1,004 results

Multidrug-resistant Cutibacterium avidum isolated from patients with acne vulgaris and ...
https://doi.org/10.1016/j.jgar.2021.12.021
Journal of Global Antimicrobial Resistance; Koizumi J, Nakase K et. al.

Jan 13th, 2022 - Cutibacterium avidum, a human skin bacterium, rarely causes infectious diseases. It has been recently shown that C. acnes, another member of the genus Cutibacterium, acts as an opportunistic pathogen in surgical site infections. However, the antim...

TIMP2 genetic variation rs4789932 may associate with an increased risk of developing ac...
https://doi.org/10.1111/jocd.14749
Journal of Cosmetic Dermatology; Wen X, Du H et. al.

Jan 13th, 2022 - Acne vulgaris is a common chronic inflammatory cutaneous disorder that has a higher prevalence in adolescents and young adults. Previous studies have indicated that both genetic and environmental factors contribute to its risk. The protein encoded...

Low dose oral isotretinoin for the treatment of adult patients with mild-to-moderate ac...
https://doi.org/10.1111/dth.15311
Dermatologic Therapy; Al Muqarrab F, Almohssen A

Jan 10th, 2022 - Acne vulgaris is one of the most common dermatologic complaints. Recently, isotretinoin has been used as an off-label indication for the treatment of mild-to-moderate grades of acne not responding to conventional treatment. Its conventional recomm...

Antiandrogenic activity of Riboflavin 5'-phosphate (FMN) in 22Rv1 and LNCaP human prost...
https://doi.org/10.1016/j.ejphar.2022.174743
European Journal of Pharmacology; Choi YH, Kim J et. al.

Jan 10th, 2022 - The androgen receptor is a hormone activated transcription factor that regulates the development and maintenance of male characteristics and represents one of the most well-established drug targets, being implicated not only in prostate cancer but...

Single-center, assessor-blind study to evaluate the efficacy and safety of DA-5520 topi...
https://doi.org/10.1111/jocd.14693
Journal of Cosmetic Dermatology; Han HS, Park JW et. al.

Jan 5th, 2022 - Unlike various topical treatment options for acne vulgaris, options for acne scars mostly involve invasive interventions. So far, only a few clinical trials have investigated the effects of topical treatment for acne scars. We evaluated the safety...

see more →

Guidelines  3 results

Management of acne vulgaris: summary of NICE guidance.
https://doi.org/10.1136/bmj.n1800
BMJ (Clinical Research Ed.); Xu J, Mavranezouli I et. al.

Sep 22nd, 2021 - Management of acne vulgaris: summary of NICE guidance.|2021|Xu J,Mavranezouli I,Kuznetsov L,Stephen Murphy M,Healy E,|

Japanese Dermatological Association Guidelines: Guidelines for the treatment of acne vu...
https://doi.org/10.1111/1346-8138.14355
The Journal of Dermatology; Hayashi N, Akamatsu H et. al.

May 22nd, 2018 - The Guidelines for the Treatment of Acne Vulgaris of the Japanese Dermatological Association was first published in Japanese in 2008 and revised in 2016 and 2017. These guidelines (GL) indicate the standard acne treatments in Japan and address pha...

Evidence-based recommendations for the diagnosis and treatment of pediatric acne.
https://doi.org/10.1542/peds.2013-0490B
Pediatrics Eichenfield LF, Krakowski AC et. al.

May 3rd, 2013 - Acne vulgaris is one of the most common skin conditions in children and adolescents. The presentation, differential diagnosis, and association of acne with systemic pathology differs by age of presentation. Current acknowledged guidelines for the ...

see more →

Drugs  379 results see all →

Clinicaltrials.gov  130 results

Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the Treatment of Moderate to Severe Acne Vulgaris With Photodynamic Therapy in Adults
https://clinicaltrials.gov/ct2/show/NCT05080764

Dec 20th, 2021 - The aim of this study is to test the safety and efficacy of photodynamic therapy (PDT) for the medication Ameluz® performed with the PDT-lamp BF-RhodoLED® in comparison to the respective placebo treatment for moderate to severe Acne vulgaris.

A Study of S6G5T3 in the Treatment of Acne Vulgaris
https://clinicaltrials.gov/ct2/show/NCT03761810

Dec 16th, 2021 - In this Phase 3, multi-center, double-blind, randomized, vehicle-controlled, parallel-group pivotal study, participants will be admitted only after a written informed consent has been obtained and after all inclusion/exclusion criteria have been m...

A Study of S6G5T-3 in the Treatment of Acne Vulgaris
https://clinicaltrials.gov/ct2/show/NCT03761784

Dec 16th, 2021 - In this Phase 3, multi-center, double-blind, randomized, vehicle-controlled, parallel-group pivotal study, participants will be admitted only after a written informed consent has been obtained and after all inclusion/exclusion criteria have been m...

A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Subjects With Acne Vulgaris
https://clinicaltrials.gov/ct2/show/NCT04856917

Dec 9th, 2021 - This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of Imsidolimab in adolescent and adult subjects with acne vulgaris (AV). This study also will characterize the pharmacokinetic (...

Comparative Safety and Efficacy of Two Treatments in the Treatment of Acne Vulgaris
https://clinicaltrials.gov/ct2/show/NCT02515305

Nov 8th, 2021 - The purpose of this study is to compare the safety and efficacy of Perrigo's product to an FDA approved product for the treatment acne vulgaris

see more →

News  161 results

Acute Severe Urticaria From Minocycline
https://www.mdedge.com/dermatology/article/249330/urticaria/acute-severe-urticaria-minocycline
Kathleen Dass, MD, Paul A. Greenberger, MD

Dec 1st, 2021 - To the Editor: Minocycline is a commonly prescribed semisynthetic tetracycline derivative used for long-term treatment of acne vulgaris. 1 Given the continued popularity of minocycline and other tetracyclines in treating acne, more adverse side eff.

Product News October 2021
https://www.mdedge.com/dermatology/article/247325/mixed-topics/product-news-october-2021

Oct 13th, 2021 - Opzelura FDA Approved for Atopic Dermatitis Incyte Corporation announces US Food and Drug Administration (FDA) approval of Opzelura (ruxolitinib) cream 1. 5% for the short-term and noncontinuous chronic treatment of mild to moderate atopic dermatit.

Delta Surge Looms; Vaccine Mandate for Federal Workers; 'Contagion' of Anger
https://www.medpagetoday.com/infectiousdisease/covid19/93781

Jul 28th, 2021 - Note that some links may require registration or subscription. Spurred on by the highly transmissible Delta variant and a flat-lined vaccination rate, the COVID-19 case count could reach 200,000 per day over the next 4-6 weeks, said former CDC dir...

Results of Laboratory Monitoring in Patients Taking Isotretinoin for Acne
https://www.mdedge.com/dermatology/article/242754/acne/results-laboratory-monitoring-patients-taking-isotretinoin-acne
Mohammed Al-Haddab, MD, FRCPC, Alanoud Alhuqayl, MD et. al.

Jul 9th, 2021 - Introduced in 1982, isotretinoin is a retinoid derivative that has been widely used to treat various dermatologic conditions such as acne vulgaris, rosacea, hidradenitis suppurativa, and hair folliculitis. 1 It remains one of the most effective dr.

Mental Health Support Essential for Some Patients With Acne, Says NICE
https://www.medscape.com/viewarticle/953824

Jun 28th, 2021 - The National Institute for Health and Care Excellence (NICE) has recommended that individuals severely affected by acne should receive mental health support in a new guideline on the management of acne vulgaris published on 25 June 2021. An estima...

see more →